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Aims. Patients who misuse alcohol may be at increased risk of surgical complications and poorer
function following hip replacement. Identiﬁcation and intervention may lead to harm reduction
and improve the outcomes of surgery. The aim of this study was to determine the prevalence of
biomarker elevation in patients undergoing hip replacement and to investigate any correlation
with functional scores and complications. Methods. We performed a retrospective study that
examined the proﬁle of biomarkers of alcohol misuse in 1049 patients undergoing hip replacement.
Results. Gamma-glutamyltransferase was elevated in 150 (17.6%), and mean corpuscular volume
w a se l e v a t e di n2 3( 4 %). At one year general physical health was poorer where there was
elevation of γGT, and the mental health and hip function was poorer with elevation of MCV.
There were no differences in complications. Discussion. Raised biomarkers can alert clinicians
to potential problems. They also provide an opportunity to perform further investigation and
offer intervention. Future research should focus on the use in orthopaedic practice of validated
screening questionnaires and more sensitive biomarkers of alcohol misuse. Conclusion. This
study demonstrates a potential substantial proportion of unrecognised alcohol misuse that is
associated with poorer functional scores in patients after total hip replacement.
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1. INTRODUCTION
Excess alcohol consumption confers an increased risk of morbidity and mortality in patients undergoing
surgical procedures [1, 2]. Detection of alcohol misuse and intervention is effective and cost effective at
reducing alcohol-related morbidity in the emergency department [3, 4]. Although the effect of alcohol
misuse has been investigated in orthopaedic patients [5], there is little evidence about the prevalence of
misuse in patients undergoing joint replacement and its effect on postoperative function and complications
[6, 7]. Most studies of outcome following total hip replacement do not report alcohol misuse, indeed a
recent meta-analysis of patient characteristics affecting the prognosis of hip and knee joint arthroplasty did
not report preoperative alcohol consumption [8].
Alcohol-related morbidity is a major problem—in the Scottish population there were 42.430
discharges from hospital with an alcohol-related diagnosis in 2007/8, equating to a rate of 777 per 100.000
[9]. Thirty-four percent of men and 23% of women are reported to exceed safe weekly drinking levels [10].
This has resulted in several reports by government, charity, and medical organisations targeting the causes,
identiﬁcation, and treatment of alcohol misuse [11–14]. Improved access to alcohol health workers has been
advocated [15]. Treating the consequences of alcohol misuse costs the National Health Service billions of
pound per year [16, 17]. Multicriteria decision analysis has determined that alcohol is the most harmful
substance of misuse [18].
Biomarkers can be used to identify patients with increased alcohol intake [19]. Though nonspeciﬁc,
mean corpuscular volume (MCV) and gamma-glutamyl-transferase (γGT) are the most commonly used
in clinical practice and are sensitive in the assessment of patients with high-risk drinking behaviours [20].
These are commonly available as part of routine haematological and biochemical tests at the time of surgery.
More speciﬁc biomarkers do exists (carbohydrate-deﬁcient transferrin: CDT); however, these tend to be
used in limited clinical and research situations.
The aim of this study was to describe the prevalence of elevated biomarkers in patients undergoing
hip arthroplasty. Secondary aims were to investigate whether biomarker elevation was correlated to (i)
functional scores (preoperative, and at one year) and (ii) the development of complications.
2. PATIENTS AND METHODS
At our institution, the demographic details, general health status, and speciﬁc joint patient reported function
were recorded in a prospectively collected audit database. From January 2005 to December 2006 (24
months), 1049 primary total hip replacements (THR) were performed. Patients attended a preassessment
clinic two weeksprior to surgery for medical assessment,blood tests (full blood count, urea andelectrolytes,
and liver function), the SF-12 general health questionnaire [21], and the Oxford hip score [22]. The SF-
12 provides a mental and physical component summary that is normalised to the national population.
The Oxford hip score measures disability in 12 domains on a Likert scale, with 12 representing the
least disability and 60 representing the most disability. We excluded patients undergoing arthroplasty for
rheumatoid arthritis (n = 22), a second procedure on the contralateral hip within the study period (n = 44),
and those with no preoperative functional score (n =132). Therefore, 851 patients undergoing primary THR
were included in the study group. There were 510 females (60%) and 341 males (40%). The mean age at
surgery was 66.3 years (S.D. 12.2), and the mean followup was 58 months (SD = 6.6). No patient had a
concomitant diagnosis of pernicious anaemia to account for observed macrocytosis.
We retrospectively reviewed the computerised laboratory database to determine the preoperative
γGT and MCV. γGT was determined by a kinetic colour test on an OSR6020 analyser (Olympus,
Diagnostica, Ireland). The MCV was determined by an automated analyser (XE 2100, Sysmex UK,
Wymbush, UK). CDT was not retrospectively available.
THR was performed by, or under the supervision of, one of ﬁfteen consultant orthopaedic surgeons.
Procedures were performed through either the modiﬁed Hardinge or posterior approach. The prostheses
used during the study period were the cemented Exeter stem (Stryker, Newbury, UK) or Olympia (Biomet
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FIGURE 1: Distribution of patients undergoing total hip replacement by γGT and gender.
UK, Bridgend, UK) with a cemented cup. The local laboratory upper reference limit of normal (ULN)
values was used to determine if elevation was present. This limit is set at two standard deviations above
the healthy population mean thus identifying 95% of the healthy population as below this level. The cut-
off for γGT in male patients was 55U/L and in females was 35U/L. The ULN for the MCV was 99ﬂ
(femtolitres).
Data were obtained from ISD (Information and Statistics, Edinburgh, UK) and the Scottish
Arthroplasty Project [23] to identify complications resulting in readmission to our unit, or any other hospital
in Scotland. We identiﬁed thromboembolic episodes or deaths with 90 days of surgery. We also identiﬁed
any dislocations, infection requiring readmission, or revision within one year of surgery.
Data were analysed using SPSS version 13 (Statistical Software for Social Sciences, Chicago, IL,
USA). Normally distributed data were reported using means and standard deviations (SD), while nonnormal
continuous data were reported with medians and interquartile ranges (IQRs). The Chi-squared test was used
to determine the signiﬁcance of differences between categorical data of elevated biomarkers and gender and
complications. Functional outcomes were assessed for normality, and parametric tests were, therefore, used.
Student t-tests were used to compare the mean preoperative and postoperative functional scores between
two groups on the basis of biomarker elevation.
3. RESULTS
The median γGT was 28U/L (IQR 18 to 47) and the median MCV was 91ﬂ (IQR 88 to 94). There were
150 (17.6%) patients with a γGT higher than the ULN. There were more males (n = 71, 20.8%) with
an elevated γGT than females (n = 79, 15.4%) (P = 0.047, χ2)( Figure 1) .T h e r ew e r e3 4( 4 % )p a t i e n t s
with elevated MCV (Figure 2). There was no difference in the proportion of males (n = 14, 4.1%) and
females (n =20, 3.9%) with elevated MCV (P =0.893, χ2). There were 10 patients (1.2%) with combined
elevation of both markers. The mean number of platelets was 264 (S.D. 75.1), and there was no statistical
difference in platelet numbers between those with elevated γGT (P = 0.668, t-test) or MCV (P = 0.408,
t-test).
Two hundred and ﬁfty eight (30.3%) patients did not complete one-year functional followup. A
higher number of patients with an elevated MCV (n = 20/34, 58.8%) failed to complete 1-year functional
assessment than those within the “normal” limits (n = 238/817, 29.1%) (P < 0.001, χ2). There was no
difference in loss to followup of patients with an elevatedγGT (n =49/150, 32.7%) compared with patients
with γGT below the ULN (n = 209/701, 29.8%).
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FIGURE 2: Distribution of patients undergoing total hip replacement by MCV and gender.
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FIGURE 3: Preoperative and 1 Year Oxford Hip Score in patients with normal and raised γGT.
At preoperative assessment, the Oxford Hip Score (OHS) was signiﬁcantly higher in patients with
elevation of either γGT (P = 0.007) or MCV (P = 0.010) (Figure 3). Raised γGT or MCV was not
associated with derangements of either the physical or mental component scores of the SF-12 score (Tables
1 and 2).
The Oxford score had improved by 1 year in all patients (mean improvement = 20.0, 95% CI 19.2 to
20.9, P < 0.001), as had both the physical (mean improvement = 12.2, 95% CI 11.3 to 13.2, P < 0.001)
and mental components (mean improvement = 3.7, 95% CI 2.8 to 4.7, P <0.001) of the SF-12 score. There
were no signiﬁcant differences in any of the changes in scores between those with either marker elevation
(Tables 1 and 2).
At one-year assessment, there was a signiﬁcantly poorer physical SF-12 score among those patients
with elevated preoperative γGT. In those with an elevation of MCV, there were signiﬁcantly poorer SF-12
mental scores (P = 0.026) and Oxford hip scores (P = 0.039) (Table 2).
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TABLE 1: Mean Functional Scores at preoperative assessment in patients with normal and elevated
biomarker.
Functional score (Mean, SD)
γGT MCV
Elevated Normal P value Elevated Normal P value
SF-12
Physical 28.6 (6.6) 29.2 (7.1) 0.343 27.9 (7.2) 29.1 (7.0) 0.294
Mental 46.1 (12.1) 48.2 (12.0) 0.060 44.7 (11.8) 47.9 (12.1) 0.129
Oxford Hip Score 44.8 (7.1) 42.8 (8.1) 0.007 46.6 (7.1) 43.0 (7.9) 0.010
TABLE 2: Mean function scores at 1 year assessment in patients with normal and elevated biomarkers.
Functional score (Mean, SD)
γGT MCV
Elevated Normal P value Elevated Normal P value
SF-12
Physical 39.6 (11.4) 42.2 (11.1) 0.036 37.6 (11.5) 41.8 (11.2) 0.165
Mental 51.5 (11.5) 53.0 (10.2) 0.201 46.5 (12.6) 52.8 (10.4) 0.026
Oxford Hip Score 23.7 (10.5) 22.4 (9.5) 0.231 27.9 (12.5) 22.5 (9.5) 0.039
TABLE 3: Complications in patients with normal and elevated biomarkers.
Complication
γGT MCV
Normal (n = 701) Elevated (n = 150) Normal (n = 817) Elevated (n = 34)
DVT/PE (n = 12) 9 (1.3%) 3 (2%) 11 (1.3%) 1 (2.9%)
Infection (n = 6) 5 (0.7%) 1 (0.7%) 6 (0.7%) 0
Dislocation (n = 1) 0 1 (0.7%) 1 (0.1%) 0
Fracture (n = 2) 2 (0.3%) 0 2 (0.2%) 0
Revision (n = 9) 8 (1.1%) 1 (0.7%) 8 (1.0%) 1 (2.9%)
Death 2 (0.3%) 0 1 (0.1%) 1 (2.9%)
Raised preoperative biomarkers were not associated with a difference in postoperative complications
(Table 3).
4. DISCUSSION
This study demonstrates a substantial proportion of unrecognised alcohol misuse in those undergoing total
hip replacement, which is similar to the reported national proportion of hazardous drinking [9]. It further
suggests that these patients are less likely to comply with standard functional followup. It also highlights
increased disability among patients with elevated biomarkers (1) before their operation and (2) poorer
physical and mental outcomes at 1 year. There was no signiﬁcant difference (between groups of patients
with raised biomarkers versus those with normal biomarkers) in the absolute improvement in any functional
score or rate of complications.
The MCV may be elevated in these patients due to deﬁciency of vitamin B compounds. γGT is a
liver enzyme involved in transport of amino-acids across cell membranes. It is released into the blood stream
by cellular damage. Several studies have used these biomarkers, either in isolation or in combination with
questionnaire tools. The sensitivity and speciﬁcity of γGT to detect hazardous drinking (when compared
with the CAGE questionnaire) were 0.69 and 0.82, respectively, whereas the sensitivity of MCV is lower
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at 0.27, but is more speciﬁc (0.91) than γGT [24]. The literature on MCV is contradictory; another study
reported a higher sensitivity for MCV of 0.70 [25]. Biomarkers have been used in various populations to
detect hazardous drinking [26]. γGT may be elevated by other medication or cholestasis and MCV may
be elevated by other conditions causing macrocytic anaemia such as pernicious anaemia. Carbohydrate
deﬁcient transferrin (CDT) is a biomarker of excess alcohol consumption that has shown a more favourable
test proﬁle with a reported sensitivity of 0.58 and speciﬁcity of 0.82 [24]. It is the increased speciﬁcity that
may lead to more accurate detection of alcohol misuse [26].
AlcoholmisuseisverycommonintheUKpopulationandpatientsmaypossess“hazardousdrinking”
patterns that increase their risk of harmful consequences. “Hazardous drinking” may lead to “harmful
drinking” where there is actual physical and/or mental impairment [27]. Such behaviour may lead to alcohol
dependence syndromes. The most recent UK government guidelines advise men should not regularly drink
more than three to four units (1 unit = 7.9g of ethanol per 100mL) of alcohol per day and women no than
two to three units. In the course of a week, men are advised to drink no more than 21 units per week, and
women no more than 14 units. Patterns of “binge drinking” are observed where there is episodic ingestion
of more than twice the advised daily limits [28]. The deﬁnition of a unit of alcohol varies between countries,
as do the sensible drinking guidelines [29].
Harmful drinking may result in perioperative dysrhythmia [30], immune response impairment [31],
and coagulation disorders. Wound healing and surgical site infection have been ascribed to suppression
of collagen formation [32]. There is a high risk of postoperative delirium in those with dependence and
withdrawal syndromes [33]. The stress response to surgery, mediated by the hypothalamo-pituitary axis, is
also potentiated in alcohol misuse [34]. A clinical effect of the rate of complications has been detected
in those with alcohol misuse undergoing joint replacement [5]. Alcohol misuse may also lead to the
development of secondary degenerative joint disease through osteonecrosis [7, 35].
Alcohol intake and misuse can be reliably identiﬁed by validated questionnaires [36]. The PAT tool
has been used effectively in the emergency department setting to rapidly identify harmful drinking and
direct brief interventions by an alcohol health worker (AHW) [3, 37]. The FAST [38], CAGE [39], and
RAPS4 [40] questionnaires are similar tools that would be appropriate for screening for harmful drinking
at preoperative assessment. The delivery of brief interventions has been shown to be cost effective [3].
The main limitations of this study are its retrospective nature and rate of loss to followup, which was
higheramongpatientswithelevatedbiomarkersofalcoholmisuse.Thismayleadtoanerrorinestimationof
functioninthisgroup.Ourstudyisalsolimitedbythesensitivityandspeciﬁcityofthebiomarkers.Although
there were no differences detected in the rate of complications (a secondary research question), the low
incidence of such events in either group may require a larger sample size to detect a statistically signiﬁcant
difference. Also, surgical strategies to deal with suspected alcohol misuse confound the measurement of
an effect. The use of the CDT biomarker would have been desirable but the study was limited by the
retrospective availability of γGT and MCV as standard biomarkers obtained at preoperative assessment.
These limitations encourage us to advocate prospective evaluation of patients undergoing
arthroplasty with validated alcohol use questionnaires preoperatively and a more sensitive biomarker
assay. Delivery of brief interventions in secondary care may reduce alcohol misuse and, therefore, reduce
hazardous and harmful drinking, leading to improved general health and risk of complications. Orthopaedic
surgeons should be aware of local referral options for intervention in patients with hazardous drinking.
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